National Clinical Research, Inc.

Richmond, Virginia 23294

0 studies enrolling now · 47 studies all time

What they study most

Acute Treatment of Migraine, Alzheimer Disease, Alzheimer's Disease, Atherosclerotic Cardiovascular Disease, Brain Diseases, Central Nervous System Diseases, Cognitive Impairment, Constipation, Dementia, Dementia With Lewy Bodies (DLB), Diabetes, Diabetes Mellitus, Type 2

Studies at this site

• Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine — Recruiting now
• Randomized Study in Children and Adolescents With Migraine: Acute Treatment — Recruiting now
• AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid — Running, not enrolling
• A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) — Running, not enrolling
• A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 — Running, not enrolling
• A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 — Running, not enrolling
• A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) — Completed
• Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder — Completed
• A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity — Running, not enrolling
• A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity — Running, not enrolling
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) — Running, not enrolling
• A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus — Completed
• BIG Study (Brain, Immune, and Gut Health Evaluation of Infants/Young Children Fed Infant Formula, and Later Supplemental Toddler Nutrition, With 5 Specific HMOs) — Completed
• A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT) — Completed
• Alzheimer's Plasma Extension — Running, not enrolling
• A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) — Completed
• A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4) — Completed
• Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. — Completed
• TRC-PAD Program: In-Clinic Trial-Ready Cohort — Completed
• A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities — Completed
• Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies — Completed
• Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men — Completed
• Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis — Completed
• Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension — Completed
• A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70) — Completed
• Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age — Completed
• Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine — Completed
• 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine — Completed
• Open Label Extension Study of PREOS — Completed
• TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis — Completed
• Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C) — Completed
• 6-week Safety and PD Study in Adults With NAFLD — Completed
• Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia — Status unconfirmed
• Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia — Completed
• Preference of Tegaserod vs. PEG 3350 in Patients With Constipation — Completed
• 24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms — Completed
• Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS) — Completed
• Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause — Completed
• A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone — Completed
• SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS) — Completed
• Clinical Trial for Evaluation of Vermillion's Blood Test to Predict the Probability of Peripheral Artery Disease — Completed
• Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding — Completed
• Asimadoline for the Treatment of Subjects With Irritable Bowel Syndrome — Completed
• Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects — Stopped early
• SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD) — Completed
• Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type — Completed
• Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn — Completed